IgG
abnormalities
in
HIV-positive
Malawian
women
initiating
antiretroviral
therapy
during
pregnancy
persist
after
24
months
of
treatment
Silvia
Baroncelli
a,*
,
Clementina
Maria
Galluzzo
a,
Giuseppe
Liotta
b,
Stefano
Orlando
b,
Fausto
Ciccacci
b,
Mauro
Andreotti
a,
Robert
Mpwhere
c,
Richard
Luhanga
c,
Jean
Baptiste
Sagno
c,
Roberta
Amici
a,
Maria
Cristina
Marazzi
d,
Marina
Giuliano
a aNationalCentreforGlobalHealth,IstitutoSuperiorediSanità,VialeReginaElena,299,00161Rome,Italy
b
DepartmentofBiomedicineandPrevention,UniversityofRomeTorVergata,ViaMontpellier,1,00133Rome,Italy
cDREAMProgram,CommunityofS.Egidio,POBox30355,Blantyre,Malawi d
DepartmentofHumanSciences,LUMSAUniversity,ViaTraspontina21,00193Rome,Italy
ARTICLE INFO
Articlehistory: Received24June2019
Receivedinrevisedform27August2019 Accepted3September2019
CorrespondingEditor:EskildPetersen, Aar-hus,Denmark Keywords: HIV Africa Pregnancy Hypergammaglobulinemia IgGsubclasses ABSTRACT
Objectives:HypergammaglobulinemiaandanomaliesintheIgGsubclassdistributionarecommonin HIV-infectedindividualsandpersistevenaftermanyyearsofantiretroviraltherapy(ART).Theaimofthis studywastoinvestigatetheIgGprofileanddynamicsinpregnantHIV-infectedMalawianwomeninthe OptionBera.
Methods:Thirty-seventreatment-naivewomenreceivedARTfromthethirdtrimesterofpregnancyto6 months postdelivery(endofthebreastfeedingperiod).ARTcontinuation(groupC)orinterruption (groupI)wasthendecidedonthebasisoftheCD4+cellcountatenrolment(>350or350/ml).TotalIgG andIgGsubclassesweredeterminedinmaternalserumusinganephelometricassayatbaselineandat6 and24monthspostpartum.
Results:Atenrolment,36/37womenhadIgGlevels>15g/landtherewasapredominanceoftheIgG1 isotype(morethan90%)inparallelwithunderrepresentationofIgG2(5.0%).After6monthsofART,both groupsshowedasignificantmediandecreaseintotalIgG( 3.1g/lingroupI, 3.5g/lingroupC)andin IgG1( 4.0g/land 3.6g/l,respectively),butonlyamodestrecoveryinIgG2levels(+0.16ingroupI,+0.14 g/lingroupC).Atmonth24,hypergammaglobulinemiawasstillpresentin73.7%ofwomeningroupC, althoughasignificantreductionwasobservedintotalIgGlevelandinIgG1andIgG3subclasses(p <0.0001inallcases).IgG2levelsdidnotshowanysignificantchange.IngroupIat24months,totalIgG andIgGsubclasseshadreturnedtolevelscomparabletothoseatbaseline.
Conclusions:Thebeneficialeffectsof24monthsofARTappeartobelimitedintheB-cellcompartment, withanincompletereductionoftotalIgGlevelsandnorecoveryofIgG2depletion.AshortARTperioddid nothavesignificanteffectsonIgGabnormalitiesinwomenwhointerruptedtreatment.
©2019TheAuthors.PublishedbyElsevierLtdonbehalfofInternationalSocietyforInfectiousDiseases. ThisisanopenaccessarticleundertheCCBY-NC-NDlicense(
http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
AnomaliesintheB-cellcompartmenthavebeendescribedinall thephasesofHIVinfection,withhypergammaglobulinemiaand defects in memory B-cells being the two most consistent observations(Pensierosoetal.,2013;MoirandFauci,2017).The mechanisms inducing immunoglobulin dysregulation are only partially known and are probably a consequence of systemic
immuneactivationandtheunbalancedproductionofproin flam-matorycytokines,reflectingtheT-celldysfunction(DeMilitoetal., 2004;Titanjietal.,2006;MoirandFauci,2008).
The beneficial effects of antiretroviral therapy (ART) in reversingtheimmunologicalT-celldysfunctionarealsoextended totheimprovementofB-cellcompartmentdisorders(Amuetal., 2014),buttherearecontrastingresultsregardingthetimingand quality of this normalization. Although a reduction in the hypergammaglobulinemiaafterARTinitiationiswidelydescribed (Notermansetal.,2001;Serpaetal.,2010),mostofthestudieshave reportedthepersistenceofachronicstateofB-cellhyperactivation (Regidoretal.,2011; Pogliaghiet al.,2015), consistentwiththe
* Correspondingauthor.
E-mailaddress:silvia.baroncelli@iss.it(S.Baroncelli).
https://doi.org/10.1016/j.ijid.2019.09.001
1201-9712/©2019TheAuthors.PublishedbyElsevierLtdonbehalfofInternationalSocietyforInfectiousDiseases.ThisisanopenaccessarticleundertheCCBY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/).
ContentslistsavailableatScienceDirect
International
Journal
of
Infectious
Diseases
incompleterecoveryoftheimmunologicalfunctionobservedin theT-cellcompartment.
EvenaftermanyyearsofART,B-cellcompartmentanomalies have been observed in aviremic patients (Chong et al., 2004; d’Orsognaetal.,2007;Huetal.,2015;Pogliaghietal.,2015)with IgGlevelsexceedingreferencelimits.Inparticular,thepolyclonal B-cellactivationcauses anunbalancedIgGsubclassprofilewith significantelevationofIgG1andIgG3levelsand underrepresenta-tionoftheIgG2isotype(Rauxetal.,2000;McGowanetal.,2006). The combination of these abnormalities in IgG levels and distributionhasbeenassociated witha poorresponsiveness to vaccinationsinadultsandchildren(Cagigietal.,2010)andtoa higher incidence of B-cell malignancies observed in HIV ART-treatedpatients(Bohliusetal.,2009;HentrichandBarta,2016).
InHIVpregnancy,thedysregulationofB-cells,andinparticular maternalhypergammaglobulinemia, hasa significant impacton IgGtransferfrommothertofoetus(Palmeiraetal.,2012),causinga saturationofFcRNreceptors,whichhavea keyrolein transpla-cental passage (de Moraes-Pinto et al., 1998). A reduced IgG concentrationinthecordofneonatesfrommotherswithIgGlevels of>15g/landinadequatelevelsofspecificIgGofmaternalorigin hasbeenextensively reportedinHIV-exposedinfants( Cumber-landetal.,2007;Babakhanyanetal.,2016).
Inthelastdecade,ARTadministrationtoHIV-positivewomen duringpregnancyandthebreastfeedingperiodhasresultedina strongreductionintherateofverticaltransmission(JointUnited NationsHIV/AIDSProgramme,2017);this in turnhasledtoan increasingrate of HIV-exposeduninfected (HEU) children, who neverthelesshave a significantly higher rate of morbidity and mortalityin thefirstyearsof lifecompared totheirunexposed counterparts (Brennan et al., 2016). Efforts made towards understandingthehighervulnerability ofHEUchildrenarestill inconclusive.
Inthiscontext,amaternalIgGdisordercanhaveacriticalrole consideringtheimportanceofmaternalimmunologicalprotection duringthefirst6monthsoflife,whenthehumoralresponsesto infectionsaremostlysustainedbyIgGofmaternalorigin(Simon etal.,2015).
InthisstudyinvolvingMalawianHIV-positivepregnantwomen intheOptionBera,theaimswere(1)tomonitorthemagnitude andthetimingoftotalIgGandIgGsubclassnormalization(ifany) after24monthsofART,and(2)todeterminethedurabilityofthe beneficialeffectsofARTonplasmaIgGlevelsandthedistribution ofthesubclassesinwomenwhointerruptedARTafter6months andwerefollowedupto24months.
Materialsandmethods Studypopulation
Thisstudyformspartofalargerobservationalstudy(enrolment duringFebruary2008toFebruary2009)aimedatassessingthe safetyandefficacyofARTadministrationinMalawianHIV-positive pregnantwomen(Safe MilkforAfrican Children(SMAC)study) (Giuliano et al., 2013). The study was conducted in Malawi (BlantyreandLilongwesites)withintheDREAM(DrugResource Enhancement against AIDS and Malnutrition) Program of the CommunityofS.Egidio,anItalianfaith-basednon-governmental organization.
In thisstudy, treatment-naiveHIV-infectedpregnantwomen startedARTduringpregnancy:inthepresenceofaCD4+cellcount <350cells/
m
l, theyreceiveda combination ofstavudine (30mg twicedaily),lamivudine(150mgtwicedaily),andnevirapine(200 mgtwicedaily)assoonaspossibleafterthefirsttrimesterand continueditindefinitely(groupC,continuoustherapy);or,inthe caseofaCD4+count>350/m
l,theyreceivedzidovudine(300mgtwicedaily),lamivudine,andnevirapinefromweek26ofgestation until6monthspostpartum(groupI,interruptionof treatment). Womenwereinstructedtoexclusivelybreastfeedupto6months. Afterdelivery,themotherswerevisitedmonthlyforclinicaland laboratory assessment up to24 months postpartum. Haemato-chemistryandviro-immunologicalanalyseswereperformedatthe localDREAMlaboratoriesinMalawi.Womenwereincludedinthis sub-study if they breastfed their infants for the scheduled 6 monthsandhadplasma samplesavailable atenrolment(before ART)andat6and24monthspostdelivery.
PlasmaIgGlevelsandIgGsubclasses
MaternaltotalIgGandsubclassplasmalevelsweredetermined using IgG total, IgG1, IgG2, IgG3, and IgG4 reagents(Siements; SiemensHealthcareDiagnostics)andreadbyautomated nephe-lometry (BN ProSpec System Analyzer; Siemens Healthcare Diagnostics).
Statisticalanalysis
IBMSPSSStatisticsversion25.0(IBMCorp.,Armonk,NY,USA) wasusedforthestatisticalanalyses.Resultsarepresentedasthe median values with interquartile range (IQR) or percentages. DifferenceswereevaluatedusingtheChi-squaretestorFisher’s exacttest,asappropriate,forcategoricalvariables,andbyMann– WhitneyU-testforquantitativevariables.Longitudinaldifferences weredetectedusingtheWilcoxontest,andSpearman’scorrelation coefficient was used for the correlation analysis between quantitative variables. Differences were considered statistically significantwhenp<0.05.
Ethicalconsiderations
Ethical approval was obtained from the National Health Research Committee in Malawi (approval number #486), and informedconsent was obtainedfrom allindividualparticipants includedinthestudy.
Results
The characteristics of the two groups of women (group I, interruption of treatment,n=18; groupC, continuoustherapy, n=19) are reportedin Table 1.Group C women wereolder (p =0.022),withhigherHIV-RNAlevels(p=0.020),andwithamore immunocompromised profile. The median time of ART during pregnancywas 9.0weeks, withaslightdifference betweenthe groups(groupI:7.0weeks,IQR4.5–13.0weeks;groupC:10weeks, IQR8.0–15.0weeks;p=0.051).Aftervaginaldelivery,allwomen continuedthetherapyfor6themonthsofexclusivebreastfeeding. IgGlevelsandimmunologicalparametersbeforeARTinitiation
Atenrolment,thetotalIgGconcentrationwas>15g/lforall butonewoman,with medianlevelsof 24.1g/l ingroupIand 27.8g/l in group C, and no statistically significant difference betweenthegroups(p=0.221).ThecompositionofIgGsubclasses showedapredominanceoftheIgG1isotype,whichaccountedfor morethan90%inbothgroups,aswellasanunderrepresentation ofIgG2(5.2%)(Table1).Althoughnosignificantdifferenceswere observed in IgG levels between the groups, a strong inverse correlationwasfoundbetweentotalIgGlevelsandtheCD4+cell count(r= 0.426,p=0.009;Figure1).TheassociationwithCD4+ cells was also confirmed for IgG1 and IgG3 plasma levels (r= 0.419, p=0.010;r= 0.340,p=0.039,respectively), but not forIgG2orIgG4levels.
ChangesinIgGprofileafter6monthsofART,attheendofthe breastfeedingperiod
At6months,significantimprovementsin the viro-immuno-logicalparameters wereobservedin bothgroups, andHIV-RNA plasmalevelsbecameundetectablein mostwomen (groupI:n =15,83.3%;groupC:n=16,84.3%).TheCD4+cellcountincreased significantlyfrombaselineinbothgroups(groupI:+204cells/
m
l; groupC:+182cells/m
l),andtheCD4+countremainedbelow350 cells/m
linonlysevenofthe37women.However,hypergammaglobulinemiawasstillpresentin34of the37 women, even thougha significant decreasein total IgG levelswasobservedinbothgroups(groupI: 6.5g/l,IQR 3.1to +0.05,p=0.010;groupC: 8.0g/l,IQR 3.5 to 0.50,p=0.006;
Table2,Figure2).Regardingthesubclasscomposition,thetrendin changes was similar in the two groups, with some difference: whilea significant decreasein thecytophilicisotype(IgG1and IgG3) levels was observed in group I (IgG1, p=0.004; IgG3, p=0.016) and in group C (IgG1, p<0.0001; IgG3, p<0.0001), IgG2 levels showed a modest increase that reached statistical significanceonlyforthewomeningroupI(p=0.003).IgG4levels decreased minimally (statistically significant only in group I, p=0.031).
The6–24-monthperiod
According tothe Option Bstrategy, onlygroup C, including women with a more severe viro-immunological profile at enrolment,continuedARTafterthebreastfeedingperiod.Inthis group,all womenreached HIV-RNA <50copies/ml anda CD4+ count>350cells/
m
l(median560cells/m
l,IQR 420–730cells/m
l) after24 monthsoftreatment. Thelevelsof totalIgG decreased between 6 and 24 months, but after 2 years,14of 19 women (73.7%) still had hypergammaglobulinemia, with a median IgG levelof19.0g/l(IQR14.3–23.7g/l).ThedecreaseintotalIgGwas paralleled by a significant decrease in IgG1 levels ( 2.3g/l, p<0.0001)andalesspronounceddecreaseinIgG3( 0.23g/l,p =0.453)andIgG4( 0.04g/l,p=0.004).IgG2levelsdidnotshow anysignificantchange,andafter24monthsofARTtreatmentno recoverywasobservedinplasmaandtheIgG2isotyperemained largelyunderrepresented.Asexpected,15of18womeningroupIwereviremicatmonth 24(HIV-RNAmedian3.42logcopies/ml),whiletheCD4+cellcount remainedstablewithamedianof629cells/
m
l(+66cells/m
l,IQR 21.3to+307cells/l;p=0.05)withrespecttopre-ARTvalues.All womeninthisgrouphadanIgGconcentration>15g/lat2years postpartum.ThemedianlevelofIgGreturnedtovaluessimilarto thosepre-ART(24.9g/lvs.24.1g/l;p=0.616),withnovariationin subclassdistribution.Discussion
TheseresultsshowthatinHIV-positivepregnantwomen,24 months of ART can improve the IgG abnormalities, but is not sufficienttonormalizetheIgGhyperproductionortorestorethe normal subclassdistribution.Overall,24monthsofARThadno impactontheIgG2levels,whichremainedstrongly underrepre-sented.ItwasalsofoundthatashortperiodofART(about7–10 months),althoughassociatedwithatemporaryimprovementin IgGanomalies,wasnotsufficienttomaintainthesechangesover2 yearspostpartum.
Polyclonalhypergammaglobulinemiaoccurs inthesetting of HIVinfection(Cagigietal.,2008),causedbyT-celldysregulation and bya direct interactionbetweenmatureB-cells andvirions (MoirandFauci,2008).ManystudieshavereportedthatARTcan partially reversesome immunological dysfunctionof theB-cell compartment(Chongetal.,2004;Redgraveetal.,2005;Abudulai etal.,2016),decreasingtheIgGhyperproductionoveravariable intervaloftime,dependingmostlyonthetimesinceHIVprimary
Figure1.CorrelationbetweentheCD4+cellcount(cells/ml)andtotalIgGlevels(g/ l)inHIV-positivepregnantMalawianwomenbeforeARTinitiation(r= 0.426, p=0.009).GroupI:whitedots;groupC:blackdots.
Table1
Patientcharacteristicsatenrolment;valuesareexpressedasthemedian(interquartilerange),orpercentage.
All GroupI GroupC p-Value
Number 37 18 19
Age(years) 27.0(23.0–32.0) 23.5(20.8–30.0) 30.0(25.0–33.0) 0.022 Weight(kg) 57.0(49.0–62.7) 56.9(50.6–60.8) 57.3(47.4–64.0) 0.855 Haemoglobin(g/dl) 10.3(9.5–11.1) 10.6(9.8–11.5) 9.8(9.1–10.0) 0.142 WHOclassification,I/II/III(%) 78.4/13.5/8.1 94.4/5.6/0.0 63.1/21.1/15.8 0.060 ARTduringpregnancy(weeks) 9.0(7.0–13.0) 7.0(4.5–13.0) 10(8.0–15.0) 0.051 CD4+(cells/ml) 340(214–503) 503(401–776) 223(152–302) <0.0001 HIVRNA(logcopies/ml) 4.17(3.49–4.69) 3.74(3.51–4.46) 4.54(3.78–4.75) 0.020 IgGtotal(g/l) 25.1(21.2–29.3) 24.1(19.5–27.7) 27.8(21.3–30.9) 0.221 IgG1(g/l) 23.5(18.6–28.4) 22.2(16.8–26.3) 25.3(18.9–28.3) 0.245
ProportionoftotalIgG(%) 91.8(87.5–93.9) 92.3(87.4–93.6) 91.6(87.6–94.6)
IgG2(g/l) 1.44(0.96–1.82) 1.38(0.93–1.81) 1.57(0.94–1.85) 0.753 ProportionoftotalIgG(%) 5.2(3.9–7.8) 5.4(4.2–8.0) 5.8(3.4–7.6)
IgG3(g/l) 1.30(1.07–1.78) 1.21(0.80–1.76) 1.41(1.11–1.91) 0.298 ProportionoftotalIgG(%) 5.3(4.4–6.4) 5.0(3.7–6.3) 5.9(4.6–6.6)
IgG4(g/l) 0.34(0.14–0.45) 0.31(0.12–0.44) 0.35(0.20–0.47) 0.343 ProportionoftotalIgG(%) 1.36(0.69–1.58) 1.4(0.3–1.7) 1.4(0.8–1.5)
infection(Pensierosoetal.2009;Moiretal.,2010).Althoughthe majority of these studies involved patients from developed countries, where better sanitary conditions, a lack of chronic parasite infections, and the wider availability of different therapeuticapproachescanhaveanimportantimpact,analogous effectsofARTonthememoryB-cellsandactivationofB-specific markers have been observed in the few studies performed in African cohorts, reporting incomplete recovery of the B-cell anomaliesinducedbyHIV(Longweetal.,2010;Tankoetal.,2017). ThisstudyfocusedontheIgG profile,since hypergammaglo-bulinemia in pregnancy has been associated with severe im-pairment of transplacental passage and can have important consequencesfor theclinicaloutcomeof theinfants(Abu-Raya etal.,2016).In apreviousstudyinvolvingwomen intheSMAC study,withARTinitiatedatweek26ofgestation,wecorrelatedthe highIgGlevelsofmothersatdeliverytothereducedIgGlevels observedintheir1-montholdinfants(Baroncellietal.,2018).We concluded that the short period of ART exposure may not be sufficientformaternalIgGnormalization.Hereweextendedthe study to 24 months of observation in an attempt to better understandthedynamicsofIgGlevelsanddistributioninAfrican HIV-positive pregnant women receiving ART. The inclusion of women who interrupted therapy according to the Option B strategygaveustheopportunitytoexplorethedurabilityofthe beneficialeffectsofARTontheIgGlevels.
Atbaseline,HIV-positive,treatment-naïvewomenhadmedian levelsofIgGashighas25.1g/l,confirmingthat hypergammaglo-bulinemiaiscommonintheHIV-infectedAfricanpopulation,as alreadyreportedbyusandbyothers(deMoraes-Pintoetal.,1998; Baroncellietal.,2018).Itwasalsofoundthatthehighlevelsoftotal IgGandIgG1werenotassociatedwiththeviralburden,butrather withtheCD4+ cellcount,suggestingthattheT-celldysfunction couldbetheprimaryforceleadingtothegeneraldysregulationof theimmunesystem(Malaspinaetal.,2003).Theseresultsarein agreementwiththose of previous studies that havefound IgG abnormalitiesassociatedwithmarkersofimmunoactivationand to the decline in T-cell functionality (Abudulai et al., 2016 D’Orsogna et al., 2007; Tanko et al., 2017). The IgG isotype distributionwasdominatedbyIgG1,whichrepresentedmorethan 90%oftotalIgG,followedbyIgG3(5.3%),whiletheIgG2isotype, whichaccountsfor20–30%oftotalIgGinthenormalpopulation (Vidarssonetal.,2014;Puissant-Lubranoetal.,2015),accounted foronly5.2%.Thepolarizationofimmunoglobulinstowardsthe IgG1andIgG3subclassesisacharacteristicofHIV-inducedB-cell dysregulation(Rauxetal.,2000),butwecannotexcludethatthe predominanceofthecytophilicisotypeinwomencouldalsobea
consequenceofexposuretomalariainfection,whichinMalawihas a prevalenceofaround24%in thegeneral population(National Malaria Control Programme (NMCP) and ICF, 2018). Cytophilic antibodiesmediateparasite-killingresponses(Scopeletal.,2006), and their increase in populations living in areas endemic for Plasmodiumfalciparumhasbeenwidelyreported(Rouhanietal., 2015;Dobañoetal.,2019).
ThelongitudinalmonitoringoftheIgGprofileshowedasignificant reductionintotalIgG,IgG1,IgG3,andIgG4levelsinthewomeninboth groupsafter6monthsofART.Nevertheless,onlyasmallpercentageof women(8.1%)reachedIgGlevelsbelowtheclinicalcut-offindicating hypergammaglobulinemia,whilemostofthem reachedviralload suppressionandaCD4+cellrecoveryof>350cell/
m
l.Thesignificant trendinreductionofIgGandisotypesIgG1,IgG3,andIgG4(butnot IgG2)wassimilarinthetwogroups,indicatingthebeneficialeffectsof 6monthsofARTalsoinwomenstartingwithamorecompromised viro-immunologicalprofile.However,6monthsofARThadnoeffect onIgG2levelsingroupCwomen,andwasassociatedwithamodest increaseingroupIwomenthat,althoughstatisticallysignificant,did notseemtobeofclinicalrelevance.In women on continuous therapy, a slow but statistically significantprogressivedecreaseintotalIgGandIgG1continued, although73.7%ofwomenstill hadIgGlevelsabove15g/lat24 months postpartum, and no significant improvement was ob-servedintermsofsubclassproportions.AgainIgG2levelsdidnot change with ART, remaining at the pre-therapy levels. In agreement with others (Tanko et al., 2017), it was found that thepersistenceofIgGdisorderswasnotassociatedwiththeviral load(undetectableinallwomen).Indexesofimmuneactivation werenotmeasuredinthestudywomen,butitislikelythatthe persistenceofinflammatorycytokines,ahallmarkofHIV-induced immune activationstatus (Brenchleyetal.,2006;Mehrajet al., 2019), couldhave affectedIgGisotype switching(Tangyeet al., 2002)andsubclasssynthesis(Kawanoetal.,1994).
ItisinterestingtonotethatthebeneficialeffectofARTonIgG levelsingroupIwomenwasonlytransitory,and18monthsafter theinterruptionofARTallwomenhadpre-ARTIgGvalues,while theCD4+ cellcountsremainedhigher withrespecttobaseline. Althoughfunctionaltestswerenotperformed,thestudyresults confirmthat thehumoraldysfunctionsin patientstreatedwith ARThavea differentialtiminginrecoverywithrespecttoCD4+ cells,probablydependingonthepatient’sinitialimmunological condition(d’Orsogna et al.,2007; Moir et al.,2010; Pensieroso etal.,2009).
Thisstudyhasseverallimitations.Thepatientsamplesizewas limited, but thelow degreeof variabilityin IgG measurements
Table2
Patientviro-immunologicalcharacteristicsat6and24monthspostpartum;valuesarereportedasthemedian(interquartilerange),orpercentage.
6Months 24Months
GroupI(n=18) GroupC(n=19) GroupI(n=18) GroupC(n=19)
ARTregimen AZT3TCNVP d4T3TCNVP None d4T3TCNVP
CD4+(cells/ml) 733(585–940) 402(333–539) 629(492–875) 560(420–734) CD4+increase(cells/ml) +204(50–366) +182(116–271) 35( 191to+47.5) +197(91–258) HIVRNA>50copies/ml,n(%) 3(16.7%) 3(15.7%) 15(83.3%) 0(0%) IgGtotal(g/l) 20.5(17.9–22.5) 21.1(18.8–28.2) 24.9(21.4–27.8) 19.0(14.3–23.7) PatientswithIgG>15g/l(%) 15/18(83.3%) 19/19(100%) 18/18(100%) 14/19(73.7%)
IgG1(g/l) 17.5(15.7–20.3) 19.4(15.9–25.6) 23.6(19.2–27.4) 16.4(12.8–21.6) IgG1change(g/l) 4.0( 8.6to+0.2) 3.6( 8.3to 1.4) +3.7(+1.5to+8.4) 2.3( 5.4to 0.7) IgG2(g/l) 1.47(1.25–1.89) 1.59(1.15–2.20) 1.36(1.13–1.77) 1.43(1.20–2.13) IgG2change(g/l) +0.16(+0.05to+0.27) +0.14( 0.04to+0.40) 0.11( 0.46to+0.07) 0.20( 0.17to+0.05) IgG3(g/l 1.02(0.61–1.31) 1.10(0.79–1.41) 1.10(0.83–150) 0.97(0.8–1.34) IgG3change(g/l) 0.25( 0.52to+0.03) 0.23( 0.50to 0.09) +0.03( 0.10to+0.33) 0.23( 0.50to 0.09) IgG4(g/l) 0.19(0.12–0.32) 0.27(0.14–0.34) 0.23(0.13–0.33) 0.21(0.12–0.34) IgG4change(g/l) 0.02( 0.19to+0.11) 0.04( 0.12to+0.02) +0.02( 0.46to+0.03) 0.04( 0.10to+0.00) ART,antiretroviraltherapy;AZT,zidovudine;3TC,lamivudine;NVP,nevirapine;d4T,stavudine.
allowsustobequiteconfidentregardingthevalidityofthedata. Unfortunatelyitwasnotpossibletoperformfunctionaltestsonthe B-cellcompartment,whichwouldhaveallowedamorecomplete analysisofthehumoraldysfunction.Further,IgGreferenceranges basedmostlyonWesternpopulationvalueswereused,whichcan differ from those of African populations (Pieters et al., 1997; Bénigueletal.,2004)andcouldmaketheevaluationoftheIgG abnormalitiesinapopulationalreadyexposedtoenvironmental factorsthathaveanimpactonthereconstitutionoftheimmune profileduringARTdifficult.
InconclusionitwasfoundthatinMalawianwomenreceiving ART,thetrendofIgGrecoveryisprogressivebutslowandisstill incomplete after 24 months in terms of total IgG levels and proportions.
Considering the physiological importance of IgG acquisition throughtransplacentalpassageforinfanthealth,thereductionof hypergammaglobulinemia in HIV-positive pregnant women should bemonitored under the current Option B+approach to assessthebenefitsofthestrategyinreducingtheriskofinfection inHIV-exposedinfants.
Figure2.LongitudinalchangesintotalIgGandsubclasses.Valuesareexpressedasthemedian+standarderror.(A)TrendoftotalIgGlevels;groupIgreydots,groupCwhite dots.GraphsB–EshowtheIgGsubclasslevels.Greybars:T1(pre-ART);whitebars:month6(endofbreastfeedingperiod);dottedbars:month24(endofstudyperiod).
Funding
ThisworkwassupportedbyagrantfromtheMinistryofHealth, Rome,Italy (grantnumber 3C04/1), by Esther-Italy,Ministryof Health(grantnumber9M34).
Conflictofinterest
Theauthorsdeclarethattheyhavenoconflictofinterest. Acknowledgements
WethankAlessandraMatteiandStefaniaDonniniforproviding secretarialhelp,MarcoMirra,MassimilianoDiGregorio,Stefano Lucattini,andLucaFuciliforITsupport,andFerdinandoCostaand PatriziaCocco fortechnicalsupport.WearegratefultoRiccardo d’AmicofortheprecioustechnicalsupportwiththeBNProSpec SystemAnalyzer,andtoallthemotherswhoparticipatedinour study.
References
AbudulaiLN,FernandezS,CorscaddenK,HunterM,KirkhamLA,PostJJ,etal. Chronic HIV-1 infection induces B-cell dysfunction that is incompletely resolvedbylong-termantiretroviraltherapy.JAcquirImmuneDeficSyndr 2016;71:381–9.
Abu-RayaB,KollmannTR,MarchantA,MacGillivrayDM.Theimmunesystemof HIV-exposeduninfectedinfants.FrontImmunol2016;7:383.
AmuS,Lavy-ShahafG,CagigiA,HejdemanB,NozzaS,LopalcoL,etal.Frequencyand phenotypeofBcellsubpopulationsinyoungandagedHIV-1infectedpatients receivingART.Retrovirology2014;11:76.
BabakhanyanA,EkaliGL,DentA,KazuraJ,NguasongJT,FodjoBAY,etal.Maternal humanimmunodeficiencyvirus-associatedhypergammaglobulinemiareduces transplacentaltransferofimmunoglobulinGtoPlasmodiumfalciparumantigens inCameroonianneonates.OpenForumInfectDis2016;3:ofw092.
BaroncelliS,GalluzzoCM,LiottaG,AndreottiM,MancinelliS,MphwereR,etal. DeficitofIgG2inHIV-positivepregnantwomenisresponsibleofinadequate IgG2levelsintheirHIV-uninfectedchildreninMalawi.MedMicrobiolImmunol 2018;207:175–82.
BéniguelL,BégaudE,CognasseF,GabriéP,MbolidiCD,SabidoO,etal.Identification ofgerminalcenterBcellsinbloodfromHIV-infecteddrug-naiveindividualsin CentralAfrica.ClinDevImmunol2004;11:23–7.
BohliusJ,SchmidlinK,CostagliolaD,FatkenheuerG,MayM,Caro-MurilloAM,etal. CollaborationofObservationalHIVEpidemiologicalResearchEurope(COHERE) Study Group. Incidence and risk factors of HIV-related non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohortstudy.AntivirTher2009;14:1065–74.
BrenchleyJM,PriceDA,SchackerTW,AsherTE,SilvestriG,RaoS,etal.Microbial translocationisacauseofsystemicimmuneactivationinchronicHIVinfection. NatMed2006;12:1365–71.
BrennanAT, Bonawitz R, Gill CJ, Thea DM, KleinmanM, Useem J, et al. A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children. AIDS 2016;30:2351–60.
CagigiA,NilssonA,DeMilitoA,ChiodiF.BcellimmunopathologyduringHIV-1 infection:lessonstolearnforHIV-1vaccinedesign.Vaccine2008;26:3016–25. CagigiA,NilssonA,PensierosoS,ChiodiF.DysfunctionalB-cellresponsesduring HIV-1 infection: implication for influenza vaccination and highly active antiretroviraltherapy.LancetInfectDis2010;10:499–503.
ChongY,IkematsuH,KikuchiK,YamamotoM,MurataM,NishimuraM,etal. SelectiveCD27+(memory)BcellreductionandcharacteristicBcellalterationin drug-naiveandHAART-treatedHIVtype1-infectedpatients.AIDSResHum Retroviruses2004;20:219–26.
CumberlandP,ShulmanCE,MaplePA,BulmerJN,DormanEK,KawuondoK,etal. MaternalHIVinfectionandplacentalmalariareducetransplacentalantibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis 2007;196:550–7.
de Moraes-Pinto MI, Verhoeff F, Chimsuku L, Milligan PJ, Wesumperuma L, BroadheadRL,etal.Placentalantibodytransfer:influenceofmaternalHIV infectionandplacentalmalaria.ArchDisChild1998;79:F202–5.
DeMilitoA,NilssonA,TitanjiK,ThorstenssonR,ReizensteinE,NaritaM,etal. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoralimmunityinHIV-1infection.Blood2004;103:2180–6.
DobañoC,SantanoR,VidalM,JiménezA,JairoceC,UbillosI,etal.Differential patternsofIgGsubclassresponsestoPlasmodiumfalciparumantigensinrelation tomalariaprotectionandRTS,Svaccination.FrontImmunol2019;10:439. D’Orsogna LG, Krueger RG, Elizabeth J, McKinnon EJ, Martyn A, French MA.
Circulating memory B-cell subpopulationsare affecteddifferently by HIV infectionandantiretroviraltherapy.AIDS2007;21:1747–52.
GiulianoM,AndreottiM,LiottaG,JereH,SagnoJB,MaulidiM,etal.Maternal antiretroviraltherapyforthepreventionofmother-to-childtransmissionofHIV inMalawi:maternalandinfantoutcomestwoyearsafterdelivery.PLoSOne 2013;8:e68950.
HentrichM,BartaS.HIV—associatedhematologicalmalignancies.Cham:Springer International Publishing; 2016 Holder Springer International Publishing SwitzerlandeBook.
HuZ,LuoZ,WanZ,WuH,LiW,ZhangT,etal.HIV-associatedmemoryBcell perturbations.Vaccine2015;33:2524–9.
KawanoY, NomaT, Yata J. Regulation of human IgG subclassproduction by cytokines.IFN-gammaandIL-6actantagonisticallyintheinductionofhuman IgG1butadditivelyintheinductionofIgG2.JImmunol1994;153:4948–58. LongweH,GordonS,MalambaR,FrenchN.CharaterisingBcellnumbersand
memoryBcellsinHIVinfectedanduninfectedMalawianadults.BMCInfectDis 2010;10:280.
MalaspinaA,MoirS,KottililS,HallahanCW,EhlerLA,LiuS,etal.Deleteriouseffect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 2003;170:5965–72.
McGowanJP,ShahSS,SmallCB,KleinRS,SchnipperSM,ChangCJ,etal.Relationship of serum immunoglobulinand IgG subclasslevels to race,ethnicityand behavioralcharacteristicsinHIVinfection.MedSciMonit2006;12:CR11–6. MehrajV,RamendraR,IsnardS,DupuyFP,LebouchéB,CostiniukC,etal.CXCL13asa
biomarkerofimmuneactivationduringearlyandchronicHIVinfection.Front Immunol2019;10:289.
MoirS,FauciAS.PathogenicmechanismsofB-lymphocytedysfunctioninHIV disease.JAllergyClinImmunol2008;122:12–9.
MoirS,BucknerCM,HoJ,WangW,ChenJ,WaldnerAJ,etal.Bcellsinearlyand chronicHIVinfection:evidenceforpreservationofimmunefunctionassociated withearlyinitiationofantiretroviraltherapy.Blood2010;116:5571–9. MoirS,FauciAS.B-cellresponsestoHIVinfection.ImmunolRev2017;275:33–48. NationalMalariaControlProgramme(NMCP)andICF.Malawimalariaindicator survey2017.Lilongwe,Malawi,andRockville,Maryland,USA:NMCPandICF; 2018At:https://dhsprogram.com/pubs/pdf/MIS28/MIS28.pdf.[AccessedMay 2019].
NotermansDW,deJongJJ,GoudsmitJ,BakkerM,RoosMT,NijholtL,etal.Potent antiretroviraltherapyinitiatesnormalizationofhypergammaglobulinemiaand adeclineinHIVtype1-specificantibodyresponses.AIDSResHumRetroviruses 2001;17:1003–8.
Palmeira P, Quinello C, Silveira-Lessa AL,Zago CA, Carneiro-SampaioM. IgG placentaltransferinhealthyandpathologicalpregnancies.ClinDevImmunol 2012;2012:985646.
PensierosoS,CagigiA,PalmaP,NilssonA,CapponiC,FredaE,etal.TimingofHAART definestheintegrityofmemoryBcellsandthelongevityofhumoralresponsesin HIV-1vertically-infectedchildren.ProcNatlAcadSciUSA2009;106:7939–44. PensierosoS,GalliL,NozzaS,Ruffin N,Castagna A,TambussiG,etal. B-cell
subsetalterationsandcorrelatedfactorsinHIV-1infection.AIDS2013;15: 27:1209–17.
PietersH,BrandCE,BadenhorstPN,HendricksML.ImmunoglobulinGsub-class concentrationsinSouthAfricanadults:ethnicdifferencesandreferenceranges. BrJBiomedSci1997;54:104–9.
PogliaghiM,RipaM,PensierosoS,TolazziM,ChiappettaS,NozzaS,etal.Beneficial effects of cART Initiated during primary and chronic HIV-1 infection on immunoglobulin-expression ofmemoryB-cell subsets. PLoS One 2015;10: e0140435.
Puissant-LubranoB,PeresM,ApoilP,Congy-JolivetN,RoubinetF,BlancherA. ImmunoglobulinIgA,IgD,IgG,IgMandIgGsubclassreferencevaluesinadults. ClinChemLabMed2015;53:e359–61.
RauxM,FinkielsztejnL,Salmon-CéronD,BouchezH,ExclerJL,DulioustE,etal.IgG subclassdistributioninserumandvariousmucosalfluidsofHIVtype1-infected subjects.AIDSResHumRetroviruses2000;16:583–94.
RedgraveBE,StoneSF,FrenchMAH,KruegerR,JamesIR,PriceP.Theeffectof combination antiretroviral therapy on CD5 B cells, B-cell activation and hypergammaglobulinaemiainHIV-1-infectedpatients.HIVMed2005;6:307– 12.
RegidorDL,DetelsD,BreenEC,WidneyDP,JacobsonLP,PalellaF,etal.Effectof highlyactiveantiretroviraltherapyonbiomarkersofB-lymphocyteactivation andinflammation.AIDS2011;25:303–14.
RouhaniM,ZakeriS,MehriziAA,DjadidND.Comparativeanalysisoftheprofilesof IgGsubclass-specificresponsestoPlasmodiumfalciparumapicalmembrane antigen-1andmerozoitesurfaceprotein-1innaturallyexposedindividuals livinginmalariahypoendemicsettings.IranMalarJ2015;14:58.
Scopel KKG, Fontes CJF, Ferreira MU, Braga EM. Factors associated with immunoglobulinGsubclasspolarizationinnaturallyacquiredantibodiesto Plasmodiumfalciparummerozoitesurfaceproteins:across-sectionalsurveyin BrazilianAmazonia.ClinVaccineImmunol2006;13:810–3.
Serpa J, Haque D, Valayam J, Breaux K, Rodriguez-Barradas MC. Effect of combinationantiretroviraltreatmentontotalproteinandcalculatedglobulin levelsamongHIV-infectedpatients.IntJInfectDis2010;14S:e41–4. SimonAK,HollanderGA,McMichaelA.Evolutionoftheimmunesysteminhumans
frominfancytooldage.ProcBiolSci2015;282:1821.
TangyeSG,FergusonA,AveryDT,MaCS,HodgkinPD.IsotypeswitchingbyhumanB cells is division-associated and regulated by cytokines. J Immunol 2002;169:4298–306.
TankoF,SoaresAP,MullerTL,GarrettNJ,SamsunderN,KarimQA,etal.Effectof antiretroviraltherapyonthememoryandactivationprofilesofBcellsin HIV-infectedAfricanwomen.JImmunol2017;198:1220–8.
TitanjiK,DeMilitoA,CagigiA,ThorstenssonR,GrutzmeierS,AtlasA,etal.Lossof memoryBcellsimpairsmaintenanceoflong-termserologicmemoryduring HIV-1infection.Blood2006;108:1580–7.
JointUnitedNationsHIV/AIDSProgramme.EndingAIDSprogresstowardsthe 90-90-90targets—globalAIDSupdate2017.Geneva:UNAIDS;2017Availableonline
at: http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_upda-te_2017_en.pdf.[AccessedMay2019].
VidarssonG,DekkersG,RispensT.IgGsubclassesandallotypes:fromstructureto effectorfunctions.FrontImmunol2014;5:520.